Drug interactions
Eribulin + Pomalidomide
Severity: Minor
Eribulin and Pomalidomide: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Eribulin is a P-glycoprotein substrate and weak inhibitor, and pomalidomide is also a P-gp substrate. Any increase in pomalidomide exposure is theoretical and likely small, with no established clinically important effect.
What this interaction means in plain words
Eribulin and Pomalidomide have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Eribulin belongs to Oncology; Pomalidomide belongs to Miscellaneous.
Why it happens
Possible weak P-glycoprotein inhibition by eribulin reducing efflux of pomalidomide; not clinically established.
What to do
No dose change is generally needed. Monitor blood counts as is routine for both drugs.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Eribulin and Pomalidomide, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Eribulin
Other interactions of Pomalidomide
- Deferiprone + Pomalidomide Major
- Ethinyl estradiol-drospirenone + Pomalidomide Major
- Fluvoxamine + Pomalidomide Major
- Apalutamide + Pomalidomide Moderate
- Brivaracetam + Pomalidomide Moderate
- Carbamazepine + Pomalidomide Moderate
Frequently asked questions
Can I take Eribulin with Pomalidomide?
MediHelp rates the interaction as minor. Eribulin and Pomalidomide have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Eribulin is a P-glycoprotein substrate and weak inhibitor, and pomalidomide is also a P-gp substrate. Any increase in pomalidomide exposure is theoretical and likely small, with no established clinically important effect.
How serious is the interaction between Eribulin and Pomalidomide?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No dose change is generally needed. Monitor blood counts as is routine for both drugs.
What other medicines interact with Eribulin?
MediHelp also lists interactions of Eribulin with, for example, Adagrasib, Amiodarone, Amisulpride. The full list is on the Eribulin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
